The US Food and Drug Administration (FDA) has granted accelerated approval to Talon Therapeutics' Marqibo (vinCRIStine sulfate LIPOSOME injection). Marqibo, a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine ...
Talon Therapeutics has reported a net income applicable to common stock of $29.76m, or $1.35 per share, for the third quarter ended 30 September 2012 compared to a net loss applicable to common stock of $1.71m, or $0.08 per share, for the ...
Tags: Marqibo, Talon launch, strategic transaction